GL Pharm Tech Past Earnings Performance
Past criteria checks 0/6
GL Pharm Tech has been growing earnings at an average annual rate of 22.6%, while the Pharmaceuticals industry saw earnings growing at 8.3% annually. Revenues have been growing at an average rate of 20.2% per year.
Key information
22.6%
Earnings growth rate
35.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 20.2% |
| Return on equity | -30.5% |
| Net Margin | -14.4% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How GL Pharm Tech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 26,033 | -3,749 | 9,012 | 2,377 |
| 30 Sep 23 | 25,081 | -2,389 | 8,041 | 2,437 |
| 30 Jun 23 | 22,095 | -1,679 | 7,360 | 2,306 |
| 31 Mar 23 | 19,325 | 797 | 5,988 | 1,883 |
| 31 Dec 22 | 16,729 | -790 | 5,684 | 1,968 |
| 30 Sep 22 | 14,466 | -1,602 | 5,003 | 2,396 |
| 30 Jun 22 | 12,271 | -2,757 | 4,728 | 2,796 |
| 31 Mar 22 | 11,942 | -4,502 | 4,454 | 2,732 |
| 31 Dec 21 | 12,426 | -3,727 | 3,190 | 2,974 |
| 30 Sep 21 | 11,652 | -4,082 | 3,340 | 2,383 |
| 30 Jun 21 | 11,725 | -3,371 | 3,132 | 2,189 |
| 31 Mar 21 | 12,182 | -3,599 | 3,070 | 2,684 |
| 31 Dec 20 | 11,988 | -3,356 | 3,104 | 2,518 |
| 30 Sep 20 | 9,630 | -3,648 | 2,429 | 2,666 |
| 30 Jun 20 | 9,772 | -4,180 | 2,500 | 2,487 |
| 31 Mar 20 | 10,029 | -6,967 | 2,472 | 2,296 |
| 31 Dec 19 | 10,608 | -5,515 | 2,488 | 2,221 |
| 30 Sep 19 | 12,226 | -5,505 | 2,775 | 2,014 |
| 30 Jun 19 | 10,911 | -5,844 | 3,170 | 1,538 |
| 31 Mar 19 | 9,668 | -3,369 | 2,938 | 1,817 |
| 31 Dec 18 | 7,998 | -5,350 | 3,295 | 1,680 |
| 30 Sep 18 | 6,487 | -4,619 | 2,858 | 1,720 |
| 30 Jun 18 | 5,446 | -4,105 | 2,154 | 2,138 |
| 31 Mar 18 | 3,826 | -4,310 | 2,118 | 1,550 |
| 31 Dec 17 | 2,414 | -4,237 | 1,466 | 1,459 |
Quality Earnings: A204840 is currently unprofitable.
Growing Profit Margin: A204840 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A204840 is unprofitable, but has reduced losses over the past 5 years at a rate of 22.6% per year.
Accelerating Growth: Unable to compare A204840's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A204840 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (36.1%).
Return on Equity
High ROE: A204840 has a negative Return on Equity (-30.52%), as it is currently unprofitable.